<i>CREBBP</i> histone acetyltransferase domain mutations predict response to mTOR inhibition in relapsed/refractory follicular lymphoma
Emil Kumar(Queen Mary University of London), Jessica Okosun(Queen Mary University of London), Findlay Bewicke‐Copley(Queen Mary University of London), Karina Close(Queen Mary University of London), Anne J. Novak(Mayo Clinic), Maria Calaminici(Queen Mary University of London), Koorosh Korfi(Queen Mary University of London), Alejo Efeyan(Spanish National Cancer Research Centre), Stephen M. Ansell(Mayo Clinic), Michael R. Green(Harvard University), Michael Leukam(Beth Israel Deaconess Medical Center), Andrew Clear(Queen Mary University of London), Jude Fitzgibbon(Queen Mary University of London), Barrie Peck(Cancer Research Center), James A. Heward(Queen Mary University of London), Jun Wang(South China Agricultural University), Jessica Scott(University of Chicago), Thomas E. Witzig(WinnMed), R. Siebert(Christian-Albrechts-Universität zu Kiel), Sonali M. Smith(University of Chicago)
Cited by 1
Related Papers
mTOR: from growth signal integration to cancer, diabetes and ageing
|Nature Reviews Molecular Cell Biology|2010|4k
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
mTORC1 Senses Lysosomal Amino Acids Through an Inside-Out Mechanism That Requires the Vacuolar H <sup>+</sup> -ATPase
|Science|2011|1.6k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Graphene and graphene oxide: biofunctionalization and applications in biotechnology
|Trends in biotechnology|2011|1.5k